Cancer. Nauseas and vomiting.
Conditions
Interventions
First time: 32 patients will receive dry extract of ginger powder, in capsules at a dose of 1000 mg / day and 32 will receive a placebo substance at the same dosage. The placebo chosen for a microcrys
Other
Sponsors
Hospital das Clínicas Universidade Federal de Goiás - GO
Hospital das Clínicas Universidade Federal de Goiás - GO
Eligibility
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Aged between 20 and 80 years; Individuals apt of swallowing capsules; Individuals with a confirmed diagnosis of cancer, being treated with chemotherapy ; Individuals who have undergone at least one CT cycle with the same chemotherapeutic agent and who have experienced nausea or vomiting as a result of such treatment; Individuals with platelet counts> 100 000/microliters before the initialcycle.
Exclusion criteria
Exclusion criteria: Individuals with ginger allergy or who have made use of it in the last week; Patients on heparin or other anticoagulant medication or who have some bleeding disorder; Patients submitted to chemoterapy associated radiotherapy during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of nausea and vomiting as assessed by the Multinational Association on Supportive Care in Cancer (MASCC). It is intended to verify a reduction of at least 2 units in the intensity and frequency of nausea and vomiting. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life as measured by the EORTC QLQ-C30 assessment method. It is expected to improve, at any intensity, on the psychometric properties of EORTEC QLQ-C30. | — |
Countries
Brazil
Contacts
Public ContactAdriele Freitas
Hospital das Clínicas Universidade Federal de Goiás - GO
Outcome results
None listed